Liisa Bayko
Stock Analyst at Evercore ISI Group
(4.47)
# 337
Out of 4,667 analysts
78
Total ratings
53.12%
Success rate
21.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SVRA Savara | Downgrades: In-Line | $7 → $5 | $3.13 | +59.74% | 3 | Nov 13, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $21.21 | +65.02% | 4 | Oct 30, 2024 | |
| EDIT Editas Medicine | Maintains: In-Line | $7 → $3 | $2.41 | +24.48% | 4 | Oct 23, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $405 → $360 | $317.09 | +13.53% | 9 | Aug 8, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $210 → $260 | $248.79 | +4.51% | 1 | Jun 25, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: In-Line | $27 → $2 | $2.66 | -24.81% | 2 | Jun 18, 2024 | |
| ANTX AN2 Therapeutics | Maintains: In-Line | $7 → $2 | $1.30 | +53.85% | 3 | May 16, 2024 | |
| ETNB 89bio | Maintains: Outperform | $37 → $33 | $7.98 | +313.53% | 4 | May 15, 2024 | |
| AKRO Akero Therapeutics | Maintains: Outperform | $50 → $38 | $30.64 | +24.04% | 3 | May 15, 2024 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | $438 | $451.23 | -2.93% | 17 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $14 | $17.86 | -21.61% | 4 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $0.86 | +1,291.47% | 1 | Jul 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $80 | $46.40 | +72.41% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $10 | $7.30 | +36.99% | 4 | Apr 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $9.58 | +87.89% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $8.05 | +210.56% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $62 | $9.08 | +582.82% | 4 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $66 → $60 | $47.26 | +26.96% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $8.75 | +300.00% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $45.75 | -47.54% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $9.97 | +200.90% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $3.44 | +190.70% | 1 | Feb 5, 2020 |
Savara
Nov 13, 2024
Downgrades: In-Line
Price Target: $7 → $5
Current: $3.13
Upside: +59.74%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $21.21
Upside: +65.02%
Editas Medicine
Oct 23, 2024
Maintains: In-Line
Price Target: $7 → $3
Current: $2.41
Upside: +24.48%
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $317.09
Upside: +13.53%
Alnylam Pharmaceuticals
Jun 25, 2024
Maintains: Outperform
Price Target: $210 → $260
Current: $248.79
Upside: +4.51%
Aerovate Therapeutics
Jun 18, 2024
Downgrades: In-Line
Price Target: $27 → $2
Current: $2.66
Upside: -24.81%
AN2 Therapeutics
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $1.30
Upside: +53.85%
89bio
May 15, 2024
Maintains: Outperform
Price Target: $37 → $33
Current: $7.98
Upside: +313.53%
Akero Therapeutics
May 15, 2024
Maintains: Outperform
Price Target: $50 → $38
Current: $30.64
Upside: +24.04%
Vertex Pharmaceuticals
Apr 11, 2024
Upgrades: Outperform
Price Target: $438
Current: $451.23
Upside: -2.93%
Sep 22, 2023
Maintains: Outperform
Price Target: $30 → $14
Current: $17.86
Upside: -21.61%
Jul 6, 2023
Initiates: Outperform
Price Target: $12
Current: $0.86
Upside: +1,291.47%
Jun 6, 2023
Upgrades: Outperform
Price Target: $60 → $80
Current: $46.40
Upside: +72.41%
Apr 20, 2023
Maintains: Outperform
Price Target: $13 → $10
Current: $7.30
Upside: +36.99%
Mar 28, 2023
Initiates: Outperform
Price Target: $18
Current: $9.58
Upside: +87.89%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $8.05
Upside: +210.56%
Jul 6, 2022
Upgrades: Outperform
Price Target: $62
Current: $9.08
Upside: +582.82%
Jun 23, 2022
Downgrades: In-Line
Price Target: $66 → $60
Current: $47.26
Upside: +26.96%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $8.75
Upside: +300.00%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $45.75
Upside: -47.54%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $9.97
Upside: +200.90%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $3.44
Upside: +190.70%